In summary, 13 of the 14 anti-flotillin-1/2-positive patients for whom medical records could be evaluated had relapses, radiological signs of disseminated demyelination, and no evidence for a disorder other than MS, ex post fulfilling the revised diagnostic criteria of relapsing-remitting MS [24]. The gene discussed is FLOT1; the disease is myeloid sarcoma.